Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Novartis
Daiichi Sankyo
US Army
Farmers Insurance
Chinese Patent Office
Johnson and Johnson
Merck
Healthtrust
Teva

Generated: October 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,758,733

« Back to Dashboard

Which drugs does patent 8,758,733 protect, and when does it expire?


Patent 8,758,733 protects LATISSE and is included in one NDA. There has been one Paragraph IV challenge on Latisse.

This patent has fifteen patent family members in six countries.

Summary for Patent: 8,758,733

Title:Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
Abstract: The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.
Inventor(s): Ahluwalia; Gurpreet (Orange, CA), Beddingfield; Frederick C. (Pacific Palisades, CA), Edwards; Sydney G. (Aliso Viejo, CA), Whitcup; Scott M. (Laguna Hills, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:13/738,732
Patent Claim Types:
see list of patent claims
Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Allergan
LATISSE
bimatoprost
SOLUTION/DROPS;TOPICAL022369-001Dec 24, 2008ATRXYesYes► Subscribe► Subscribe METHOD OF INCREASING EYELASH GROWTH
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,758,733

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,298,518Method of enhancing hair growth► Subscribe
7,351,404Method of enhancing hair growth► Subscribe
8,986,715Method of enhancing hair growth► Subscribe
9,216,183Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists► Subscribe
8,101,161Method of enhancing hair growth► Subscribe
8,263,054Method of enhancing hair growth► Subscribe
8,632,760Method of enhancing hair growth► Subscribe
8,038,988Method of enhancing hair growth► Subscribe
8,926,953Method of enhancing hair growth► Subscribe
9,226,931Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,758,733

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan4143034► Subscribe
Japan2005521672► Subscribe
Hong Kong1203839► Subscribe
European Patent Office2802331► Subscribe
European Patent Office2250996► Subscribe
European Patent Office1471876► Subscribe
Canada2475106► Subscribe
Australia2013208002► Subscribe
Australia2012261499► Subscribe
Australia2010227111► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Farmers Insurance
Moodys
Express Scripts
Novartis
Teva
Fuji
US Army
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot